Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History

NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application covering what may be the first new salts, co-crystals and polymorphs of psilocybin in history.

CEO Dr. Sam Clark said the discovery marks “a new chapter in psychedelic medicinal chemistry,” as the company worked with one of the most well-studied compounds “to create novel breakthroughs previously not thought possible." Read more HERE.

MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected

MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. 

“We have seen a meaningful acceleration in enrollment over the last few months since our full set of study sites were activated early this year with 25 patients enrolled just in the last 30 days,” said director and CEO Robert Barrow of the clinical-stage biopharma company.

Read more HERE.

Canada: PharmAla Nabs First-Ever Approval Of MDMA Treatment Outside Clinic, Plus Survey Reveals Real-World Use And Access Trends

MDXX-class molecules and clinical-grade MDMA developer PharmAla Biotech and distribution partner Shaman Pharma Corp. (affiliated with GMP-compliant CCrest Labs) received Health Canada’s approval to provide proprietary LaNeo MDMA capsules to a Canadian physician for patient treatment …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.